XML 19 R54.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaborative and Other Relationships (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Co-promotion profit sharing formula |
Until GAZYVA First Non-CLL FDA Approval | 40.0 | %
After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
First Non-CLL GAZYVA FDA Approval means the FDA’s first approval of GAZYVA in an indication other than CLL. First GAZYVA Threshold Date means the earlier of (1) the date of the First Non-CLL GAZYVA FDA Approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least $150.0 million or (2) the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached $150.0 million. Second GAZYVA Threshold Date means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached $500.0 million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.
Pretax profit sharing formula |
Until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Revenues from unconsolidated joint business |
| For the Years Ended December 31,
(In millions) | 2013 |  | 2012 |  | 2011
Biogen Idec’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA (1) | $ | 1,085.2 |  |  | $ | 1,031.7 |  |  | $ | 872.7 |
Reimbursement of selling and development expenses in the U.S. for RITUXAN | 2.1 |  |  | 1.6 |  |  | 6.1 |
Revenue on sales in the rest of world for RITUXAN | 38.7 |  |  | 104.6 |  |  | 117.8 |
Total unconsolidated joint business revenues | $ | 1,126.0 |  |  | $ | 1,137.9 |  |  | $ | 996.6 |
Summary of activity related to collaboration with Acorda |
| For the Years Ended December 31,
(In millions) | 2013 |  | 2012 |  | 2011
Upfront and milestones payments made to Acorda (1) | $ | — |  |  | $ | — |  |  | $ | 25.0 |
Total cost of sales related to royalties and commercial supply of FAMPYRA reflected within our statements of income | $ | 24.3 |  |  | $ | 20.2 |  |  | $ | 6.5 |
Mechanism for reimbursement, under the amended agreement amounts payable |
|  |  |  |  | Rates should Sobi exercise its option right(3)
Royalty and Net Revenue Share Rates: | Method |  | Rate prior to 1st commercial sale in the Sobi Territory: |  | Base Rate following 1st commercial sale in the Sobi Territory: |  | Rate during the Reimbursement Period:
Sobi rate to Biogen Idec on net sales in the Sobi Territory | Royalty |  | N/A |  | 10 to 12% |  | Base Rate plus 5%
Biogen Idec rate to Sobi on net sales in the Biogen Idec North America Territory | Royalty |  | 2% |  | 10 to 12% |  | Base Rate less 5%
Biogen Idec rate to Sobi on net sales in the Biogen Idec Direct Territory | Royalty |  | 2% |  | 15 to 17% |  | Base Rate less 5%
Biogen Idec rate to Sobi on net revenue(1) from the Biogen Idec Distributor Territory(2) | Net Revenue Share |  | 10% |  | 50% |  | Base Rate less 15%
(1) | Net revenue represents Biogen Idec’s pre-tax receipts from third-party distributors, less expenses incurred by Biogen Idec in the conduct of commercialization activities supporting the distributor activities.
(2) | The Biogen Idec Distributor Territory represents Biogen Idec territories where sales are derived utilizing a third-party distributor.
(3) | A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen Idec to Sobi on sales in the Biogen Idec territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.
Summary of activity related to collaboration with AbbVie Inc. |
| For the Years Ended December 31,
(In millions) | 2013 |  | 2012 |  | 2011
Total development expense incurred by the collaboration | $ | 133.4 |  |  | $ | 128.0 |  |  | $ | 105.2 |
Biogen Idec’s share of development expense reflected within our consolidated statements of income | $ | 71.0 |  |  | $ | 65.6 |  |  | $ | 54.2 |
Summary of activity related to collaboration with Portola Pharmaceuticals, Inc. |
| For the Years Ended December 31,
(In millions) | 2013 |  | 2012 |  | 2011
Total expense incurred by the collaboration | $ | 1.6 |  |  | $ | 18.8 |  |  | $ | 1.1 |
Total expense reflected within our consolidated statements of income, excluding upfront and milestone payments | $ | 1.6 |  |  | $ | 14.2 |  |  | $ | 0.9 |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pretax Profit Sharing Formula [Table Text Block] + References No definition available. + Details
Name: | biib_PretaxProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Mechanism for reimbursement, under the amended agreement amounts payable. + References No definition available. + Details
Name: | biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from unconsolidated joint business. + References No definition available. + Details
Name: | biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of activity related to collaboration with company five. + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanyFiveTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of activity related to collaboration with company four. + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanyFourTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of activity related to collaboration with company seven. + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration